CRISPR Therapeutics AG
Long

No brainer alpha at a cheap price

1) Crisper has a lot of cash on hand to survive through tightening of QE and fund pipeline without dilution
2) Potential takeover by VRTX or other compamy at current prices VERY possible.

Disclaimer